¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå : °Ë»çº°, Ä¡·á¹ýº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°
Noonan Syndrome Market, By Test, By Treatment, By Route of Administration, By End Users, By Distribution Channel, By Geography
»óǰÄÚµå : 1671840
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,197,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,640,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,772,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ´©³­ ÁõÈıº ½ÃÀåÀº 2025³â 11¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â¿¡´Â 21¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGRÀº 9.7%·Î È®´ëµÉ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 11¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£: 2025-2032³â CAGR: 9.70% 2032³â °¡Ä¡ ¿¹Ãø 21¾ï 1,000¸¸ ´Þ·¯
±×¸². ´©³­ ÁõÈıº ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025
Noonan Syndrome Market-IMG1

´©³­ ÁõÈıºÀº ½Åü ¹ß´Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ½ÉÀå Àå¾Ö, ¼·½Ä Àå¾Ö, ¹ß´Þ Áö¿¬, ÃâÇ÷ Àå¾Ö¸¦ ÀÏÀ¸Å°´Â µå¹® À¯Àü ÁúȯÀÔ´Ï´Ù. ´©³­ ÁõÈıºÀº Ãâ»ý ÀüÀÇ ¼ºÀå°ú ¹ß´ÞÀ» ´ã´çÇÏ´Â À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇØ À¯¹ßµË´Ï´Ù. À¯¾Æ±â¿¡¼­ ´©³­ ÁõÈıºÀÇ ÀϹÝÀûÀΠ¡Èķδ ´« °£°ÝÀÌ ³Ð°í, ¸ñÀÌ ±¸ºÎ·¯Á® Àְųª, ³·Àº ¸Ó¸®¼± µîÀÇ ºñÁ¤»óÀûÀÎ ¾ó±¼ÀÌ ÀÖ½À´Ï´Ù. ´Ù¸¥ ¡Èķδ ½ÉÀå Àå¾Ö, Àú½ÅÀå, ¼·½Ä Àå¾Ö, ÃâÇ÷ Àå¾Ö µîÀÌ ÀÖ½À´Ï´Ù. °ü·Ã °Ç°­ ¹®Á¦¸¦ ½Å¼ÓÇÏ°Ô Áø´ÜÇÏ°í °ü¸®ÇÏ¸é ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±×·¯³ª ´©³­ ÁõÈıºÀÇ Ä¡·á¹ýÀº ¾øÀ¸¸ç Ä¡·á´Â Áõ»óÀÇ °ü¸®¸¦ ¸ñÀûÀ¸·ÎÇÕ´Ï´Ù. ¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀåÀº ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â Ä¡·á ¼Ö·ç¼ÇÀ» Á¦°øÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀåÀº ÀÓ»ó °ü¸®¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡ÇÔ¿¡ µû¶ó À¯Àü¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °ßÀεǰí ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü°ú Ä¡·á °³ÀÔµµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Ä¡·á ¿É¼ÇÀÇ ºÎÁ·Àº Å« Àå¾Ö°¡ µÇ¾ú½À´Ï´Ù. ¶ÇÇÑÀÌ Áúº´Àº Èñ±ÍÇϰí ȯÀÚ ¼ö°¡ Àû´Ù´Â ¹®Á¦µµ ÀÖ½À´Ï´Ù. ±×·¯³ª, ÇöÀç ÁøÇà ÁßÀÎ ¾à¹° °³¹ß ¹× À¯ÀüÀÚ °Ë»ç¿¡ °üÇÑ ¿¬±¸´Â ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Ç¥Àû ¿ä¹ýÀÇ °³¹ß°ú ÀáÀçÀûÀÎ ¾à¹°ÀÇ ÀÓ»ó½ÃÇèÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀÇ ÀáÀç·ÂÀ» ´õ¿í °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

ÀÌ º¸°í¼­´Â ¼¼°è ´©³­ ÁõÈıº ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð ¹× º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ ¼­·Î ´Ù¸¥ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È Çà·Ä¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.

¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î Á¦°øÇÕ´Ï´Ù.

º» ¿¬±¸ÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷Àº Laboratory Corporation of America, Invitae Corporation, Sema4, CENTOGENE NV, Paragon Genomics, Inc., Illumina, Inc., NeoGenomics Laboratories, Eurofins Scientific, PerkinElmer Inc., Bio-Rad Laboratories, Inc., Novo Nordi, Genentech, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚ´Â ¼¼°è ´©³­ ÁõÈıº ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå, °Ë»çº°, 2020-2032³â,(10¾ï ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå, Ä¡·á¹ýº°, 2020-2032³â,(10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â,(10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2020-2032³â,(10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â,(10¾ï ´Þ·¯)

Á¦9Àå ¼¼°èÀÇ ´©³­ ÁõÈıº ½ÃÀå, Áö¿ªº°, 2020-2032³â, °¡Ä¡(10¾ï ´Þ·¯)

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ºÐ¼®°¡ Ãßõ

Á¦12Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Noonan Syndrome Market is estimated to be valued at USD 1.10 Bn in 2025 and is expected to reach USD 2.11 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.10 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 9.70% 2032 Value Projection: USD 2.11 Bn
Figure. Noonan Syndrome Market Share (%), By Region, 2025
Noonan Syndrome Market - IMG1

Noonan syndrome is a rare genetic disorder that affects physical development and causes heart defects, feeding issues, developmental delays, and bleeding problems. It is caused by mutations in genes that help direct growth and development before birth. Some common signs of Noonan syndrome in infancy include unusual facial features such as widely spaced eyes, a webbed neck, a low hairline or widow's peak hairline. Other signs include heart defects, short stature, feeding issues, and bleeding problems. Prompt diagnosis and management of associated health issues can help improve outcomes. However, there is no cure for Noonan syndrome and treatment aims to manage symptoms. The global Noonan syndrome market aims to provide treatment solutions to improve the quality of life of patients.

Market Dynamics:

The global Noonan syndrome market is driven by the rising prevalence of the genetic disorder along with growing awareness about its clinical management. Early diagnosis and therapeutic intervention have also boosted the market growth. However, lack of treatment options acts as a major roadblock. The market also faces challenges due to the rare nature of the disease and small patient pool. Nonetheless, ongoing research on drug development and genetic testing offers lucrative opportunities in the market. Development of targeted therapies and clinical trial of potential drugs can further strengthen the market potential over the forecast period.

Key Features of the Study:

This report provides in-depth analysis of the global Noonan syndrome market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global Noonan syndrome market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Laboratory Corporation of America, Invitae Corporation, Sema4, CENTOGENE N.V., Paragon Genomics, Inc., Illumina, Inc., NeoGenomics Laboratories, Eurofins Scientific, PerkinElmer Inc., Bio-Rad Laboratories, Inc., Novo Nordisk A/S, Pfizer Inc., USV Private Limited, Merck KGaA, and Genentech, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global Noonan syndrome market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Noonan syndrome market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Noonan Syndrome Market, By Test, 2020-2032, (USD Bn)

5. Global Noonan Syndrome Market, By Treatment, 2020-2032, (USD Bn)

6. Global Noonan Syndrome Market, By Route of Administration, 2020-2032, (USD Bn)

7. Global Noonan Syndrome Market, By End Users, 2020-2032, (USD Bn)

8. Global Noonan Syndrome Market, By Distribution Channel, 2020-2032, (USD Bn)

9. Global Noonan Syndrome Market, By Region, 2020 - 2032, Value (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â